Atria Wealth Solutions Inc. Buys 643 Shares of Zoetis Inc. (NYSE:ZTS)

Atria Wealth Solutions Inc. lifted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 4.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 16,618 shares of the company’s stock after purchasing an additional 643 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in Zoetis were worth $3,280,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ZTS. Cary Street Partners Investment Advisory LLC increased its stake in Zoetis by 7.4% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 93,735 shares of the company’s stock worth $16,308,000 after acquiring an additional 6,457 shares during the last quarter. Peak Financial Advisors LLC bought a new position in Zoetis during the 4th quarter valued at approximately $2,776,000. BLB&B Advisors LLC raised its position in shares of Zoetis by 1.9% in the 3rd quarter. BLB&B Advisors LLC now owns 60,872 shares of the company’s stock worth $10,591,000 after acquiring an additional 1,107 shares in the last quarter. Ninety One UK Ltd raised its position in shares of Zoetis by 13.1% in the 4th quarter. Ninety One UK Ltd now owns 108,293 shares of the company’s stock worth $21,374,000 after acquiring an additional 12,537 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. raised its position in shares of Zoetis by 10.9% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 183,564 shares of the company’s stock worth $36,230,000 after acquiring an additional 17,976 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on ZTS. Barclays decreased their target price on Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research report on Tuesday, April 23rd. Stifel Nicolaus decreased their target price on Zoetis from $215.00 to $195.00 and set a “buy” rating for the company in a research report on Tuesday, April 2nd. StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Piper Sandler reaffirmed an “overweight” rating and set a $195.00 price objective (down previously from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. Finally, The Goldman Sachs Group raised their price objective on Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a research report on Wednesday, January 17th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $218.00.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 363 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $197.74, for a total value of $71,779.62. Following the transaction, the executive vice president now directly owns 20,417 shares in the company, valued at approximately $4,037,257.58. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In the last three months, insiders have sold 2,209 shares of company stock worth $371,293. Insiders own 0.12% of the company’s stock.

Zoetis Stock Up 3.3 %

ZTS stock opened at $158.42 on Friday. The business has a 50 day moving average of $171.79 and a 200 day moving average of $179.31. The company has a quick ratio of 2.00, a current ratio of 3.36 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The firm has a market cap of $72.45 billion, a PE ratio of 31.25, a price-to-earnings-growth ratio of 2.42 and a beta of 0.85.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing the consensus estimate of $1.32 by ($0.08). Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The business had revenue of $2.21 billion for the quarter, compared to analysts’ expectations of $2.19 billion. During the same quarter in the prior year, the business posted $1.15 earnings per share. The business’s revenue for the quarter was up 8.5% on a year-over-year basis. On average, research analysts forecast that Zoetis Inc. will post 5.79 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be paid a dividend of $0.432 per share. The ex-dividend date is Thursday, April 18th. This represents a $1.73 annualized dividend and a yield of 1.09%. Zoetis’s dividend payout ratio is 34.12%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.